Business
Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., January 06, 2026--Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, today announced its upcoming corporate presentation at the 2026 J.P. Morgan Healthcare Conference ("JPM 2026") on Monday, January 12 at 8:00 a.m. PT. The presentation marks an important milestone for Kardigan as it enters 2026 with multiple clinical data readouts expected across its late-stage portfolio of personalized CV medicines in specific types
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":688,"height":232,"url":"https://media.zenfs.com/en/business-wire.com/420d4a3c0821b2c8f7706268a818029f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LJd4DvEo39nywUUEKnUc6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/420d4a3c0821b2c8f7706268a818029f","width":688,"height":232}},"lazy":false},{"type":"text","content":"Andy Pasternak appointed chief strategy officer, bringing extensive leadership in biopharmaceutical business development and company growth","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Clinical data readouts expected in 2026 across all three late-stage programs, marking a significant step forward in addressing unmet cardiovascular needs in dilated cardiomyopathy, hypertension, and calcific aortic valve stenosis","length":229,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., January 06, 2026--(BUSINESS WIRE)--Kardigan™, a heart health company modernizing cardiovascular (CV) drug development, today announced its upcoming corporate presentation at the 2026 J.P. Morgan Healthcare Conference ("JPM 2026") on Monday, January 12 at 8:00 a.m. PT. The presentation marks an important milestone for Kardigan as it enters 2026 with multiple clinical data readouts expected across its late-stage portfolio of personalized CV medicines in specific types of dilated cardiomyopathy (DCM), hypertension, and calcific aortic valve stenosis (CAVS).","length":621,"tagName":"p"},{"type":"text","content":""2025 was a landmark year for Kardigan, beginning with the public introduction of our vision to build the cardiovascular company of the future and ending with a powerful foundation for what we expect to achieve in 2026 and beyond. Over the course of the past year, we acquired Prolaio™, a leading CV clinical intelligence company, initiated three late-stage clinical trials in diseases where no treatments exist, and expanded our shareholder base with several leading biotech investors," said Tassos Gianakakos, co-founder, chief executive officer, and chair of Kardigan. "As we continue to execute our vision, I’m proud to welcome Andy to the Kardigan Executive Com...